Listing 11.10 ALS in 2026: How SSA Fast-Tracks Amyotrophic Lateral Sclerosis SSDI Claims as a Compassionate Allowance Under Bulbar Onset and Spinal Onset Pathways With Gold Coast and Updated El Escorial Diagnostic Criteria, ALSFRS-R Tracking, and the 2026 FDA-Approved Treatment Picture

By Anthony Albert, Benefits Research Director, Disability Exchange · Updated June 30, 2026 · SSA Blue Book Section 11.00 Neurological (Adult)

Amyotrophic lateral sclerosis is the rare claim where the SSDI process is supposed to move fast. SSA has classified ALS as a Compassionate Allowance condition since 2008. That puts ALS files into the CAL queue at DDS and, when the diagnostic record is clean, decisions can come back in 30 to 60 days. The 5-month SSDI waiting period was eliminated for ALS by Public Law 116-126, signed in December 2020 and effective for ALS claims filed after July 23, 2020. The 24-month Medicare waiting period was also waived for ALS by the same statute.

Even with that fast-track infrastructure, ALS claims still get denied or delayed when the diagnostic record is incomplete. The most common reason is missing electromyography (EMG) findings of active and chronic denervation in the required number of body regions. SSA wants the file to read like a neuromuscular clinic note, not a primary care summary.

This guide walks Listing 11.10 with the verbatim text, the Gold Coast criteria that replaced the revised El Escorial framework in 2020, the current FDA-approved 2026 treatment picture, ALSFRS-R tracking, the Compassionate Allowance pathway, and the bulbar versus spinal onset distinction. Two worked Massachusetts and Florida cases close the file. See If You Qualify.

What 11.10 Actually Says

Here is the verbatim text of Listing 11.10 from the SSA Blue Book Section 11.00 Neurological (Adult):

That is the entire listing. There are no Paragraph A, B, or C subparts. SSA decides 11.10 entirely on diagnostic confirmation under 11.00H. There is no functional severity test, no marked-or-extreme limitation framework, no assistive device requirement. The diagnosis itself meets the listing.

11.00H controls what counts as a confirmed ALS diagnosis. The section requires documentation from an acceptable medical source (a licensed physician, usually a neurologist or neuromuscular specialist) describing the clinical features and the electrophysiologic findings consistent with ALS. The agency does not require you to mention a specific set of criteria by name, but in practice the strongest files cite either the Gold Coast criteria or the revised El Escorial criteria.

The Compassionate Allowance Track for ALS

ALS is one of the original conditions on the SSA Compassionate Allowance (CAL) list. The CAL designation does not change the medical eligibility standard. It changes the queue. When the disability examiner at DDS identifies a CAL condition on intake, the file is routed for expedited review. The agency target for CAL claims is 30 days from receipt to allowance, though actual times vary.

To get the CAL flag on the file at intake:

• Include "ALS" or "amyotrophic lateral sclerosis" in the impairment description. On the SSA-3368 (Disability Report), list ALS first.
• Submit the neurology consultation note with the application. The file moves faster when the diagnostic evidence is already in the record on day one, rather than being requested from the treating provider.
• Submit the EMG/NCS report. The single most important document. Without electrodiagnostic evidence the CAL flag may still apply but the examiner will request the report, adding weeks.
• Submit a one-page brain and cervical/thoracic/lumbar MRI summary. SSA wants to confirm that structural mimics (spinal cord compression, multifocal motor neuropathy, cervical myelopathy) have been ruled out.

Public Law 116-126 (the ALS Disability Insurance Access Act) waives the 5-month SSDI waiting period for ALS claimants who file after July 23, 2020. That means SSDI cash benefits start the month after entitlement, not five months later. The same statute waives the 24-month Medicare waiting period. ALS claimants are eligible for Medicare the month they become entitled to SSDI cash benefits.

The 2020 Gold Coast Criteria (Now Preferred Over El Escorial)

The Gold Coast criteria were published in 2020 by Shefner and colleagues to simplify ALS diagnosis. They have replaced the older Awaji-Shima revision of the El Escorial criteria at most U.S. neuromuscular centers because they reduce false negatives in early-stage disease.

Gold Coast requires all of the following:

1. Progressive motor impairment documented by history or repeated clinical assessment, preceded by normal motor function.
2. Presence of upper motor neuron AND lower motor neuron dysfunction in at least one body region, OR lower motor neuron dysfunction in at least two body regions.
3. Investigations excluding other disease processes that could explain the findings (mimics).

The four body regions for Gold Coast and El Escorial are bulbar, cervical, thoracic, and lumbosacral. Upper motor neuron signs include spasticity, hyperreflexia, pathological reflexes (Hoffmann, Babinski), pseudobulbar affect, and emotional lability. Lower motor neuron signs include weakness, atrophy, fasciculations, and EMG evidence of active and chronic denervation.

The Revised El Escorial Criteria (Still Commonly Cited)

The Awaji-Shima revision of the El Escorial criteria, published in 2008, was the standard before Gold Coast. Many U.S. neurologists still use the El Escorial framework. The categories matter because some treating physicians document the diagnosis as "clinically probable laboratory-supported ALS" or "clinically definite ALS" using this framework.

The Awaji-revised El Escorial categories:

• Clinically definite ALS: upper motor neuron and lower motor neuron signs in three body regions.
• Clinically probable ALS: upper motor neuron and lower motor neuron signs in two body regions with at least some UMN signs rostral to the LMN signs.
• Clinically probable laboratory-supported ALS: upper motor neuron and lower motor neuron signs in one body region, OR upper motor neuron signs in one region, plus EMG evidence of acute denervation in at least two limbs.
• Clinically possible ALS: upper motor neuron and lower motor neuron signs in only one body region.

For SSA purposes, any of the first three categories satisfies 11.10. Clinically possible ALS by itself may need additional supporting evidence (genetic testing for SOD1, C9orf72, FUS, TARDBP, or follow-up exam showing disease progression).

EMG and Nerve Conduction Studies: The Core Lab Test

Electromyography is the diagnostic anchor for 11.10. The EMG report should describe:

• Active denervation: fibrillation potentials and positive sharp waves in the affected muscles.
• Chronic denervation: large-amplitude, long-duration, polyphasic motor unit action potentials with reduced recruitment and increased firing rate.
• Distribution: findings in at least two of the four body regions (bulbar, cervical, thoracic, lumbosacral). Some neuromuscular centers also report on the thoracic paraspinals as a useful additional region.
• Fasciculation potentials: spontaneous, irregularly firing motor units. Awaji-revised El Escorial considers fasciculations equivalent to fibrillation potentials when the morphology matches active denervation.

Nerve conduction studies should show normal or near-normal sensory responses (sensory involvement argues against ALS and points to multifocal motor neuropathy or other mimics) and reduced compound muscle action potential (CMAP) amplitudes in the affected muscles. F-wave studies and repetitive nerve stimulation are sometimes added to exclude conduction block (multifocal motor neuropathy) and neuromuscular junction disorders (myasthenia gravis, Lambert-Eaton).

MRI and Structural Mimics

11.00H expects the file to show that structural causes of upper and lower motor neuron findings have been excluded. The standard imaging is brain MRI plus cervical spine MRI. Additional thoracic and lumbar MRI is added if the clinical exam suggests cord pathology at those levels.

The most important mimics to exclude:

• Cervical spondylotic myelopathy: cervical cord compression producing UMN signs in the legs and LMN signs in the arms. Surgical decompression resolves it. MRI shows the compression.
• Multifocal motor neuropathy (MMN) with conduction block: pure LMN syndrome that responds to IVIG. NCS shows conduction block. Treatable.
• Inclusion body myositis: distal-predominant and asymmetric weakness in older patients. Muscle biopsy shows rimmed vacuoles and inflammatory infiltrate.
• Kennedy disease (spinobulbar muscular atrophy): X-linked CAG repeat in androgen receptor gene. Slowly progressive, bulbar features, gynecomastia. Genetic testing distinguishes.
• Cervical syringomyelia: central cord cavity producing dissociated sensory loss and LMN weakness. MRI shows the syrinx.
• Hexosaminidase A deficiency adult form: rare metabolic mimic. Enzyme assay distinguishes.

ALSFRS-R: Functional Tracking

The ALS Functional Rating Scale Revised (ALSFRS-R) is the standard functional tracking instrument. It is a 12-item scale, each item scored 0 to 4, with a maximum of 48. It has four subscales:

• Bulbar (items 1-3): speech, salivation, swallowing.
• Fine motor (items 4-6): handwriting, cutting food, dressing and hygiene.
• Gross motor (items 7-9): turning in bed, walking, climbing stairs.
• Respiratory (items 10-12): dyspnea, orthopnea, respiratory insufficiency.

The ALSFRS-R is not required for the SSA listing, but it is used by virtually every neuromuscular clinic to track progression. A baseline ALSFRS-R plus follow-up scores three to six months later is the single strongest documentation of disease progression. Average ALS progression is 1 to 1.5 points per month, but rates vary widely. A claimant whose ALSFRS-R drops from 40 to 32 in six months is progressing within the typical range.

Bulbar Onset Versus Spinal Onset

About 70 percent of ALS cases are spinal onset (limb weakness, atrophy, fasciculations starting in an arm, leg, or both). About 30 percent are bulbar onset (dysarthria, dysphagia, tongue fasciculations starting in the cranial nerve distribution). Bulbar onset has a shorter median survival, roughly 2 to 3 years from symptom onset compared with 3 to 5 years for spinal onset.

Bulbar Onset Presentation

Bulbar onset patients often present with progressive dysarthria, hypernasal speech, drooling, and dysphagia. Tongue exam shows atrophy and fasciculations. Gag reflex may be exaggerated (UMN) or absent (LMN). Pseudobulbar affect (involuntary emotional outbursts) is common. Weight loss from dysphagia is often the first thing the patient notices. PEG tube feeding becomes necessary in most bulbar-onset patients within 12 to 18 months of diagnosis.

Spinal Onset Presentation

Spinal onset is the classic presentation. Foot drop, hand weakness, atrophy of the thenar or first dorsal interosseous, fasciculations across multiple muscle groups. Asymmetry is the rule. The other limb usually follows within 6 to 18 months. Respiratory involvement appears later, but forced vital capacity (FVC) and seated and supine maximal inspiratory pressures should be tracked from baseline.

2026 FDA-Approved Treatment Picture

SSA does not deny ALS claims because treatment is available. ALS treatment in 2026 modestly slows progression and modestly extends survival. None of it changes the disease trajectory enough to affect listing eligibility. Current FDA-approved options:

• Riluzole (Rilutek, Tiglutik oral suspension, Exservan oral film): approved 1995. Glutamate release inhibitor. Modest survival benefit of 2 to 3 months. Standard of care. Standard dose 50 mg twice daily.
• Edaravone (Radicava, Radicava ORS): approved 2017 IV, 2022 oral. Free radical scavenger. Modest slowing of functional decline by ALSFRS-R, primarily in early-stage patients. IV dosing on a 28-day cycle is burdensome and the oral formulation has improved adherence.
• Sodium phenylbutyrate-taurursodiol (Relyvrio): approved 2022. Voluntary withdrawal by Amylyx in April 2024 after the confirmatory Phase 3 PHOENIX trial failed to show benefit. Not available in 2026.
• Tofersen (Qalsody): accelerated approval April 2023 by FDA. Antisense oligonucleotide for SOD1-mutation ALS. Lowers SOD1 protein levels. Reduces neurofilament light chain (a marker of axonal injury). The first ALS drug to target a specific genetic cause. Administered intrathecally every 28 days at specialty centers. Eligibility requires confirmed SOD1 mutation on genetic testing.

The pipeline for 2026 includes neoantigen immunotherapy trials, additional antisense approaches (TUDCA, ulefnersen for FUS, jacifusen for FUS), C9orf72 antisense and CRISPR programs, and ongoing exploration of NurOwn (autologous mesenchymal stem cell secretome) although the BrainStorm Phase 3 was negative. None of these are FDA-approved for general ALS use in 2026.

Multidisciplinary Clinic Care

The 2026 ALS Association certified clinic model is the standard of care. Patients are seen at three-month intervals by neurology, pulmonology, speech-language pathology, dietetics, physical and occupational therapy, social work, and respiratory therapy. Genetic counseling and palliative care are added as appropriate.

Key clinic interventions that DDS examiners look for in the record:

• Forced vital capacity (FVC) measurement at each visit. FVC less than 50 percent of predicted is an indication for noninvasive ventilation.
• Noninvasive ventilation (NIV / BiPAP) initiation. Improves survival and quality of life when started at FVC below 50 percent.
• PEG tube placement when weight loss exceeds 10 percent of baseline, dysphagia is severe, or FVC is dropping toward 50 percent (because PEG is harder to safely place at lower FVC).
• Augmentative and alternative communication (AAC) devices for bulbar-onset patients as speech becomes unintelligible.
• Mobility equipment including ankle-foot orthoses, manual or power wheelchairs, and home modifications.
• Riluzole and edaravone prescriptions. Documentation that the patient is on standard-of-care therapy.
• Advance directives. Discussion of tracheostomy, ventilator dependence, and end-of-life preferences.

Genetic Testing

About 10 percent of ALS cases are familial and most of those carry mutations in C9orf72, SOD1, FUS, or TARDBP. The C9orf72 hexanucleotide repeat expansion is the single most common genetic cause, accounting for roughly 30 to 40 percent of familial ALS and 5 to 10 percent of sporadic ALS in populations of European ancestry.

Genetic testing is now routinely offered in U.S. neuromuscular clinics, especially in patients with a family history of ALS or frontotemporal dementia. For tofersen eligibility, SOD1 testing is mandatory. A SOD1-positive result in a patient with classic ALS clinical features and EMG findings closes the file at DDS without much examination time.

Cognitive and Behavioral Features (ALS-FTD Spectrum)

Up to 50 percent of ALS patients have measurable cognitive or behavioral impairment, and about 15 percent meet criteria for behavioral variant frontotemporal dementia (FTD). The ALS-FTD spectrum is unified by underlying TDP-43 proteinopathy in most cases. The Edinburgh Cognitive and Behavioural ALS Screen (ECAS) is the standard bedside cognitive instrument for ALS clinics.

SSA does not require cognitive testing for 11.10 because the motor neuron findings alone satisfy the listing. But if cognitive features are documented they support both the diagnostic picture and Step 5 RFC analysis in cases where the listing is somehow contested.

How DDS Reads an ALS File

For a CAL-flagged ALS file, the DDS examiner is looking for three documents on intake:

1. Neurology or neuromuscular consultation note documenting upper motor neuron and lower motor neuron findings, the differential diagnosis considered, and the conclusion that ALS is the working diagnosis.
2. EMG and nerve conduction study report showing active and chronic denervation across at least two body regions (or one body region with UMN signs in the same region, per Gold Coast).
3. Brain and cervical spine MRI excluding structural mimics.

When those three are in the file at intake, the typical decision time is 30 to 45 days. When any of them is missing, the examiner sends a Request for Medical Evidence (RME) and the timeline extends.

Worked Example: Catherine, 56, Boston, Massachusetts

Catherine, a 56-year-old high school music teacher in Boston, noticed slurred speech and trouble swallowing thin liquids in March 2025. Her primary care physician referred her to a neuromuscular clinic at Massachusetts General. She was seen in May 2025. Exam showed dysarthria with hypernasal speech, tongue atrophy with fasciculations, brisk jaw jerk, brisk gag reflex, mild hyperreflexia in the upper extremities, and emotional lability with pseudobulbar affect. Limb strength was 5/5 except for mild weakness of finger extension on the right.

EMG in June 2025 showed active denervation (fibrillation potentials and positive sharp waves) in the tongue, the masseter, the right first dorsal interosseous, and the right tibialis anterior. Chronic denervation with large polyphasic motor units was seen in all four muscles. NCS were normal except for reduced CMAP amplitudes in the right median and right peroneal distributions. Brain and cervical spine MRI were unremarkable.

The neuromuscular specialist documented "clinically definite ALS by Gold Coast criteria with bulbar onset, UMN and LMN signs in three body regions." Catherine was started on riluzole 50 mg twice daily and oral edaravone. Genetic testing was negative for the four most common ALS genes.

Catherine filed for SSDI in July 2025 with the consultation note, EMG report, and MRI summary attached. The CAL flag was applied on intake. The DDS examiner allowed the claim in August 2025, 32 days after filing. Because she filed after July 2020, the 5-month waiting period was waived. Her first SSDI payment arrived in September 2025 covering August. Medicare entitlement began the same month under the ALS waiver.

By March 2026 Catherine's ALSFRS-R had dropped from 42 at diagnosis to 26. She had a PEG tube placed in November 2025 and was using a Tobii eye-gaze AAC device for communication. FVC was 58 percent of predicted and her pulmonologist was discussing NIV. She remained at home with her spouse and a daily home health aide.

Worked Example: Daniel, 49, Miami, Florida

Daniel, a 49-year-old commercial electrician in Miami, noticed cramping and twitching in his right calf in late 2024. He attributed it to overuse. By February 2025 he had right foot drop and started tripping on uneven sidewalks. His primary care physician referred him to neurology. Initial exam in March 2025 showed right ankle dorsiflexion 3/5, mild atrophy of the right tibialis anterior, fasciculations in both calves and the right deltoid, hyperreflexia at the right knee, and an upgoing Babinski on the right.

EMG in April 2025 showed widespread active and chronic denervation in the right tibialis anterior, right gastrocnemius, left tibialis anterior, right first dorsal interosseous, and the right C5-6 paraspinal muscles. NCS were normal in sensory studies and showed reduced CMAP amplitudes in the right peroneal and right ulnar distributions. Brain MRI and cervical, thoracic, and lumbar spine MRI were unremarkable.

The neuromuscular specialist at the University of Miami documented "clinically probable ALS by revised El Escorial, spinal onset, UMN and LMN signs in lumbosacral and cervical regions with EMG evidence in three regions." Daniel was started on riluzole and oral edaravone. Genetic testing was positive for a SOD1 D90A mutation. He was referred for tofersen consideration and began intrathecal infusions in June 2025 at the multidisciplinary clinic.

Daniel filed for SSDI in May 2025 with the consultation, EMG, and MRI reports attached. The CAL flag was applied at intake. The DDS examiner allowed the claim in June 2025, 28 days after filing. Onset was established at March 2025 based on the first neurology exam. The 5-month waiting period and the 24-month Medicare waiting period were both waived under the ALS statute.

By June 2026 Daniel's ALSFRS-R had dropped from 38 at diagnosis to 30, slower than typical progression, possibly reflecting tofersen response (his neurofilament light chain levels had decreased by about 60 percent on therapy). He was using bilateral forearm crutches and a power wheelchair for distance. FVC was 78 percent of predicted. He remained at home with his spouse.

For a parallel multiple sclerosis case under a different Section 11 listing, see our deep dive on Listing 11.09 multiple sclerosis. For spinal cord disorders see Listing 11.08 spinal cord disorders.

State Pages for Filing

If you are in Massachusetts, see our Massachusetts SSDI page. If you are in Florida, see our Florida SSDI page. Other state pages: Texas, California, New York, Pennsylvania, Ohio.

What to Include in the File at Application

For an ALS claim, the application package should include:

• Neurology or neuromuscular specialist consultation note with diagnosis stated as ALS, MND, or amyotrophic lateral sclerosis.
• EMG and nerve conduction study report describing active and chronic denervation in at least two body regions.
• Brain MRI report.
• Cervical spine MRI report. Add thoracic and lumbar spine MRI if examined.
• Laboratory studies excluding mimics (CK, B12, TSH, HIV, syphilis, paraneoplastic panel if appropriate).
• Genetic testing results if available.
• ALSFRS-R baseline and any follow-up scores.
• Pulmonary function testing (FVC, MIP, MEP) if obtained.
• Medication list (riluzole, edaravone, tofersen, others).
• HA-1152 medical source statement from the treating neurologist confirming the diagnosis.

That package gets the CAL flag and minimizes RME cycles.

Step 5 RFC Backup (Rarely Needed)

ALS rarely needs a Step 5 RFC pathway because the diagnostic listing is sufficient. In the rare case where the file is denied at the listing level (typically because EMG findings are incomplete or the diagnosis is in transition from "possible" to "probable"), the Step 5 analysis is straightforward. Any patient with progressive motor neuron disease and weakness across multiple body regions cannot perform sedentary work on a sustained basis. SSR 96-9p erosion is essentially total. Grid Rules at any age direct a finding of disabled.

Frequently Asked Questions

If you have just been diagnosed with ALS, get the application in fast. The Compassionate Allowance track exists for a reason. See If You Qualify.